Major Objectives of the Study:
# To define, describe, and forecast the global neurovascular devices market on the basis of product, disease pathology, and region.
# To provide detailed information regarding major factors influencing growth of the market (drivers, restraints, and opportunities).
# To strategically analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the overall market.
# To analyze the opportunities in the market for key stakeholders and provide details of the competitive landscape for leading market players.
# To forecast the size of the market segments with respect to four main regions, namely, North America, Europe, Asia-Pacific, and the Rest of the World (RoW).
# To strategically profile the key market players and comprehensively analyze their market shares and core competencies.
# To track and analyze competitive developments such as acquisitions, expansions, new product launches, agreements, and collaborations in the neurovascular devices/interventional neurology devices market.
Download PDF Brochure@
Global Key Players:
The key players in the neurovascular devices/interventional neurology market focused on various strategies such as product launches & enhancements; agreements and collaborations; strategic acquisitions; and expansions to increase market shares in the global market. Product launches & enhancements were the key strategies adopted by major industry players to achieve the desired market growth during 2013-2016.
This strategy was mainly adopted by Stryker Corporation (U.S.), Medtronic plc (U.S.), Johnson & Johnson (U.S.), Terumo Corporation (Japan), Penumbra, Inc. (U.S.), Abbott Laboratories (U.S.), Merit Medical Systems, Inc. (U.S.), W. L. Gore & Associates, Inc. (U.S.), and MicroPort Scientific Corporation (China). Apart from product launches & enhancements, many prominent players also adopted agreements & collaborations as the key growth strategy to strengthen market presence, enhance R&D capabilities, and to expand distribution networks to generate additional demand by sensitizing end users through an increase in availability of neurovascular products
Stryker Corporation (U.S.) held the leading position in the global market, in 2015. The company has a wide range of neurovascular products, including guidewires (such as Transend guidewires and Synchro guidewires), microcatheters (such as Excelsior SL-10 microcatheter and Excelsior 1018 microcatheter), balloon occlusion catheter (Transform occlusion balloon catheter), and detachable coils (such as Target XL detachable coils, Target Nano Detachable Coils, Target 360 Detachable Coils, and Target 3D Detachable Coils).
The company has a strong presence in North America, Europe, the Middle East, Africa, Asia-Pacific and other countries. The company has more than 30 manufacturing facilities in countries such as the U.S., China, Turkey, Germany, Ireland, Switzerland, and France. It primarily focuses on inorganic business growth strategies such as product development & commercialization, acquisitions, and market expansions. The company launched and commercialized clot retrieval device, namely, Trevo ProVue in November 2012 and acquired Synergetics USA, Inc. in April 2016, Trauson Holdings Company Limited (China) in March 2013, and Surpass Medical, Ltd. (Israel) in November 2012 to strengthen its R&D capabilities and expand its product portfolio in the global market.
Medtronic plc (Ireland) held the second position in the global market, in 2015. The company has a strong foothold in the market with a broad range of neurovascular products which include embolic coils, liquid embolics, microcatheters, guidewires, balloon catheters, clot retrieval devices, flow diversion devices, vascular embolization devices, remodeling devices, flow restoration devices, cranial repair products (such as TiMesh system and INVISx Cranial Fixation System), and shunts (such as StrataMR Adjustable Pressure Valve, Strata Adjustable Pressure Valve with Siphon Control and Strata NSC Adjustable Pressure Valve with No Siphon Control).
To strengthen its current position and to gain a larger share in the market, the company aggressively focuses on inorganic growth strategies such as product development & commercialization, acquisitions, and market expansions. During 2012–2016, the company developed and commercialized several neurovascular products such as Solitaire (TM) stent retriever device (November 2016), Pivox Oblique lateral spinal system with lateral plate for OLIF25 (July 2016), infuse bone graft (December 2015), and StealthStation electromagnetic (EM) surgical navigation system instruments (May 2015). In addition, the acquisition of Medina Medical (U.S.), Covidien plc (U.S.), Reverse Medical Corporation (U.S.), and Nfocus Neuromedical, Inc. (U.S.) enhanced its R&D capabilities and expanded its product portfolio in the global market.
Request Sample Pages@
Major Market Developments:
# In December 2016, Codman Neuro (a subsidiary of Johnson & Johnson) acquired Pulsar Vascular Inc. (US), this acquisition aimed at the enhancement of product portfolio for hemorrhagic and ischemic stroke.
# In December 2016, Terumo Corporation signed an agreement with Abbott Laboratories (U.S.) and St. Jude Medical, Inc. (U.S.). The agreement was aimed at acquisition of St. Jude Medical’s Angio-Seal and FemoSeal vascular closure & Abbott’s Vado Steerable Sheath. This agreement helped Terumo Corporation to enhance the product portfolio in minimally invasive entry site management and strengthen its visibility in the U.S. neurovascular and interventional neurology devices market.
# In July 2016, Medtronic plc launched its Pivox Oblique Lateral Spinal System with Lateral Plate for OLIF25 and Divergence-L Anterior/Oblique Lumbar Fusion System for OLIF51 for the development of OLIF (Oblique Lateral Interbody Fusion) Platform. The OLIF platform is a minimally invasive spine fusion procedures utilized for the placement of an implant into the disc space for anterior column support.
# In July 2016, Penumbra, Inc. launched ACE 68 Reperfusion Catheter for the treatment of acute ischemic stroke. It includes latest technological advancements to deliver maximum aspiration power for extracting thrombus in acute ischemic stroke patients.
# In February 2015, Terumo Corporation announced the establishment of its R&D center in Southern California (U.S.) with an investment of USD 84.0 million (~JPY 10.0 billion). The R&D center will commence operations in 2017, and is mandated to focus on R&D programs related to coronary and peripheral interventional therapies (including neurovascular surgeries).